Effect of radiative expression vector Egr1-survivin shRNA combined with irradiation on radiosensitivity of esophageal squamous cell carcinoma ECA109 cell line
WANG Haifeng, Amanguli·Aihemaiti, LU Yanrong, LV Yin, ZHANG Jinrong
Department of Radiotherapy of the Chest and Abdomen, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, China
Abstract：Objective To investigate the effect of radiative expression vector Egr1-survivin shRNA combined with irradiation on the apoptosis and radiotherapy sensitivity of esophageal squamous cell carcinoma ECA109 cells. Methods The radiative expression vector Egr1-survivin shRNA was designed and transfected into ECA109 cells by LipofectamineTM2000 before radiotherapy was started. The treatment with YM155 combined with irradiation was established as the main control. The expression levels of survivin mRNA and protein in each treatment group were detected 24 hours after treatment with qPCR and Western Blot respectively. The cell cycles and cell apoptosis of each treatment group were detected by flow cytometry 48 hours after treatment respectively. Results In ECA109 cells, the expression levels of survivin mRNA and protein were more significantly down-regulated in transfected Egr1-survivin shRNA plasmid combined with irradiation group than in YM155 combined with irradiation group, the blank control group, and the blank vector control group. Compared with the last three groups, G2 and S cycle cell rates were significantly increased, while the apoptosis rate was clearly decreased in Egr1-survivin shRNA combined with irradiation group (P<0.01) respectively). Conclusions The radiative expression vector Egr1-survivin shRNA combined with irradiation can promote the apoptosis of ECA109 cells and enhance their radiotherapy sensitivity. It promises to be a therapeutic method in conjunction with radiotherapy.
Freddie B, Jacques F, Isabelle S, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].Cancer J Clin, 2018, 68: 394-424.
Hiappa A, Andreoni B, Dionigi R, et al. A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives[J]. Crit Rev Oncol Hematol, 2018, 132: 161-168.
Ambrosini G, Adida C, Altieri D C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma[J]. Nat Med, 1997, 3(8): 917-921.
[7]
Xia H, Chen S, Huang H, et al. survivin over-expression is correlated with a poor prognosis in esophageal cancer patients[J]. Clin Chim Acta, 2015, 446: 82-85.
[8]
Zhou C, Zhang L, Xu P. Growth inhibition and chemo-radiosensitization of esophageal squamous cell carcinoma by survivin-shRNA lentivirus transfection[J]. Oncol Lett, 2018, 16(4): 4813-4820.
[9]
Weichselbaum R R, Hallahan D E, Beckett M A, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells [J]. Cancer Res, 1994, 54(16): 4266-4269.
[10]
Li Z L, Liang S, Wang Z C, et al. Expression of smac induced by the egr1 promoter enhances the radiosensitivity of breast cancer cells[J]. Cancer Gene Ther, 2014, 21(4): 142-149.
[11]
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27): 2796-2803.
[12]
Dabrowski A, Filip A, Zgodziński W, et al. Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer[J]. Folia Histochem Cytobiol, 2004, 42(3): 169-172.
[13]
Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts [J]. Cancer Res, 2007, 67(17): 8014-8021.
[14]
Li F, Aljahdali I, Ling X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? [J]. J Exp Clin Cancer Res, 2019, 38(1): 368.
[15]
Zhou Y, Song X, Jia R, et al. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma[J]. Pigment Cell Melanoma Res, 2010, 23(5): 661-674.
[16]
Wang H, Song X, Zhang H, et al. Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts [J]. Int J Cancer, 2012, 130(2): 443-453.
[17]
Seiwert T Y, Darga T, Haraf D, et al. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFeradeTM Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation[J]. Ann Oncol, 2013, 24(3): 769-776.
2020, Vol. 31 
